At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Triheptanoin 1g/kg/daydrug
Likely dose
Triheptanoin 1g/kg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ETUDE PREUVE DE CONCEPT D'UNE APPROCHE ANAPLEROTIQUE UTILISANT LA SPECTROSCOPIE RMN CEREBRALE AU PHOSPHORE-31 DANS LA MALADIE DE HUNTINGTON
Institut National de la Santé Et de la Recherche Médicale, France·interventional·Posted Jun 20, 2013·Updated Jun 11, 2026
In Brief
A Phase 2 clinical trial evaluating Triheptanoin 1g/kg/day for Huntington Disease. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this project is to study the efficacy of an anaplerotic treatment on brain energy profile evolution at an early stage of the Huntington disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedJun 2013
Primary CompletionJul 2013
TodayJul 2026
First PostedJun 20, 2013
Enrollment StartMay 1, 2013
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.0 years ago
Interventions
Triheptanoin 1g/kg/daydrug